Cart
sales@molnova.com
VUF-11222
CAS No. 1414376-84-3
VUF-11222( —— )
Catalog No. M34735 CAS No. 1414376-84-3
VUF-11222 is a CXCR3 nonmimetic peptide agonist that induces gliosis.VUF 11222 has been used in the study of retinal inflammation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 148 | In Stock |
|
| 10MG | 235 | In Stock |
|
| 25MG | 398 | In Stock |
|
| 50MG | 576 | In Stock |
|
| 100MG | 863 | In Stock |
|
| 200MG | 1163 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVUF-11222
-
NoteResearch use only, not for human use.
-
Brief DescriptionVUF-11222 is a CXCR3 nonmimetic peptide agonist that induces gliosis.VUF 11222 has been used in the study of retinal inflammation.
-
DescriptionVUF 11222 (Compound 38) is a CXCR3 non-peptide-like agonist. VUF 11222 can be used in the study of inflammation.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAutophagy
-
TargetCXCR
-
RecptorCXCR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1414376-84-3
-
Formula Weight552.33
-
Molecular FormulaC25H31BrIN
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC([N+](CC1=CC=C(C=C1)C2=C(Br)C=CC=C2)(C)C)C=3[C@]4(C(C)(C)[C@](C4)(CC3)[H])[H].[I-]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wijtmans M, et al. Chemical subtleties in small-molecule modulation of peptide receptor function: the case of CXCR3 biaryl-type ligands. J Med Chem. 2012 Dec 13;55(23):10572-83.?
molnova catalog
related products
-
AD80
AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.
-
FC131 TFA (606968-52...
FC131 TFA is a CXCR4 antagonist that inhibits the binding of [125I] -sdf-1 to CXCR4 with an IC50 value of 4.5 nM and has anti-hiv activity.
-
Ulocuplumab
Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and multiple myeloma transplantation models.
